Accessioning Unit

What we do.

The Accessioning Unit (AU) is a core service through the Duke Human Vaccine Institute (DHVI) that provides support for human and non-human clinical studies as well as small animal studies.

The AU is housed within state of the art facilities at the Duke Research and Development at RTP campus with ample space for specimen processing, storage, and retrieval for a variety of research studies. The team works closely with both internal and external investigators to ensure biorepository and accessioning needs are met and that sample shipments are requested, tracked, and received on time.

In order to best serve researchers and ensure that all proper compliance checks have been performed, we require a consultation prior to initiating any study.

Visit the AU Core Website

CIVICs
Latent Tuberculosis Study
U01/Staph A and Gram (-) Bacterial Study
Long Term Impact of HIV Infection on Kidney
Influenza P01 Grant
PRIME KNEE
Breast Cancer Studies (GMI-1359-310, AbemaImmune)
Prostate Cancer Studies (SPARC, CHAMP)
MESSI (Molecular and Epidemiological Study of Suspected Infection following COVID-19 positive subjects)
BRAVE / PEDS COVID-19 (Pediatric MESSI)
PRISM (Pediatric COVID-19)
SNOWBALL
Pfizer SARS-CoV-2 Vaccine

Shipment & Receipt of Biological Specimens

We process specimens with various temperature requirements such as ambient, 4˚C, -80˚C (dry ice), and LN2 (cryoshippers).
Packaging and set-up with shipping vendors

We work with a number of vendors for domestic and international shipping. Vendors include FedEx, UPS, Biocair, and World Courier.
AU Core as a DHVI Shared Resource

The AU provides a wide range of services for DHVI investigators such isolation and storage of plasma, serum, nasal swab, PBMC, and tissue.
Good Clinical Laboratory Practice (GCLP) Certified

All processing, storage, and shipping services are completed under established Standard Operating Procedures (SOPs) overseen and regularly audited by Duke QADVIP.